NDAORALTABLETPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIEKIRA PAK is a fixed-dose combination tablet containing dasabuvir, ombitasvir, paritaprevir, and ritonavir, approved in December 2014 for oral treatment of hepatitis C virus (HCV) infection. This direct-acting antiviral (DAA) regimen targets multiple HCV proteins (NS5A, NS5B protease, and NS3/4A protease) to achieve cure in patients with chronic HCV, particularly those with genotype 1 infection. The copackaged formulation simplifies treatment by combining four active pharmaceutical ingredients into a single dosing regimen.
Peak7.4 years to LOE
Product is in peak commercial phase with established market presence; teams typically stabilized post-launch with focus on market maintenance and regional optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIEKIRA PAK offers exposure to mature commercial execution, payer negotiations, and lifecycle management strategies in a complex therapeutic area. Career growth on this product is tied to market optimization, access expansion, and transition planning as the product approaches patent expiration.
Brand ManagerMarket Access Manager
Worked on VIEKIRA PAK (COPACKAGED) at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.